Literature DB >> 12845656

Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden.

Paul W Dickman1, Lars-Erik Holm, Göran Lundell, John D Boice, Per Hall.   

Abstract

Ionizing radiation is the only established cause of thyroid cancer, though the effect of diagnostic administration of (131)I on thyroid cancer risk appears minimal. The annual number of thyroid examinations using radioiodine is currently 5 per 1,000 individuals worldwide, so this issue is of public health importance. Our objective was to evaluate the excess risk of thyroid cancer following a range of known doses of (131)I administered for diagnostic purposes. We conducted a nationwide, population-based cohort study in Sweden including all 36,792 individuals who received (131)I for diagnostic purposes during 1952-1969 and were alive and free of thyroid cancer 2 years after exposure. Accrual of person-time at risk commenced 2 years after the first (131)I administration. Follow-up for cancer was to the end of 1998. Standardized incidence ratios (SIRs) were calculated as the ratio between the observed and expected numbers of thyroid cancers. Estimates were stratified by previous exposure to external radiation therapy to the neck, reason for thyroid examination, (131)I dose, sex, age at exposure and time since exposure. Thyroid cancers (n = 129) were diagnosed during 886,618 person-years at risk. Excess thyroid cancers were observed only among the 1,767 patients who reported previous external radiation therapy to the neck [SIR = 9.8, 95% confidence interval (CI) 6.3-14.6] and among those originally referred due to suspicion of a thyroid tumor (SIR = 3.5, 95% CI 2.7-4.4 for 11,015 patients without previous external radiation therapy). The 24,010 patients without previous exposure to external radiation therapy to the neck who were referred for a reason other than suspicion of a thyroid tumor received an estimated dose to the thyroid of 0.94 Gy. Among these patients, 36 thyroid cancers were observed compared to 39.5 expected (SIR = 0.91, 95% CI 0.64-1.26). We found no evidence that administration of (131)I for diagnostic purposes increases risk of thyroid cancer. However, our study included few patients under age 20, so the results apply primarily to exposure among adults. Our data suggest that protraction of dose may result in a lower risk than brief X-ray exposure of the same total dose. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845656     DOI: 10.1002/ijc.11258

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Thyroid cancer after chernobyl: obfuscated truth.

Authors:  Sergei V Jargin
Journal:  Dose Response       Date:  2011-02-25       Impact factor: 2.658

Review 2.  Exposing the thyroid to radiation: a review of its current extent, risks, and implications.

Authors:  Bridget Sinnott; Elaine Ron; Arthur B Schneider
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

3.  Are cancer risks associated with exposures to ionising radiation from internal emitters greater than those in the Japanese A-bomb survivors?

Authors:  Mark P Little; Per Hall; Monty W Charles
Journal:  Radiat Environ Biophys       Date:  2007-07-17       Impact factor: 1.925

4.  EANM procedure guidelines for therapy of benign thyroid disease.

Authors:  Marcel P M Stokkel; Daria Handkiewicz Junak; Michael Lassmann; Markus Dietlein; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

Review 5.  Occupation and thyroid cancer.

Authors:  Briseis Aschebrook-Kilfoy; Mary H Ward; Curt T Della Valle; Melissa C Friesen
Journal:  Occup Environ Med       Date:  2014-03-06       Impact factor: 4.402

6.  Observations on the Chernobyl Disaster and LNT.

Authors:  Zbigniew Jaworowski
Journal:  Dose Response       Date:  2010-01-28       Impact factor: 2.658

7.  Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure.

Authors:  Kyoji Furukawa; Dale Preston; Sachiyo Funamoto; Shuji Yonehara; Masahiro Ito; Shoji Tokuoka; Hiromi Sugiyama; Midori Soda; Kotaro Ozasa; Kiyohiko Mabuchi
Journal:  Int J Cancer       Date:  2012-08-16       Impact factor: 7.396

Review 8.  Potassium iodide (KI) to block the thyroid from exposure to I-131: current questions and answers to be discussed.

Authors:  Christoph Reiners; Rita Schneider
Journal:  Radiat Environ Biophys       Date:  2013-03-09       Impact factor: 1.925

9.  Increasing incidence of thyroid cancer: controversies explored.

Authors:  Yasuhiro Ito; Yuri E Nikiforov; Martin Schlumberger; Riccardo Vigneri
Journal:  Nat Rev Endocrinol       Date:  2013-01-29       Impact factor: 43.330

10.  Site-specific cancer risk in the Baltic cohort of Chernobyl cleanup workers, 1986-2007.

Authors:  Kaja Rahu; Timo Hakulinen; Giedre Smailyte; Aivars Stengrevics; Anssi Auvinen; Peter D Inskip; John D Boice; Mati Rahu
Journal:  Eur J Cancer       Date:  2013-05-15       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.